Hims & Hers Health, Inc.

Hims & Hers Health, Inc. (HIMS) Market Cap

Hims & Hers Health, Inc. has a market capitalization of $6.33B.

Financials based on reported quarter end 2025-12-31

Price: $28.82

1.83 (6.78%)

Market Cap: 6.33B

NYSE · time unavailable

CEO: Andrew Dudum

Sector: Healthcare

Industry: Medical - Equipment & Services

IPO Date: 2019-09-13

Website: https://www.forhims.com

Hims & Hers Health, Inc. (HIMS) - Company Information

Market Cap: 6.33B · Sector: Healthcare

Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.

Analyst Sentiment

59%
Buy

Based on 15 ratings

Analyst 1Y Forecast: $34.50

Average target (based on 3 sources)

Consensus Price Target

Low

$13

Median

$27

High

$60

Average

$30

Potential Upside: 2.9%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 HIMS HERS HEALTH INC CLASS A (HIMS) — Investment Overview

🧩 Business Model Overview

Hims & Hers Health Inc (HIMS) is a digital direct-to-consumer healthcare and wellness platform focused on providing accessible and affordable care through telehealth solutions. The company targets stigmatized or under-served conditions—such as sexual health, dermatology, mental health, and primary care—by leveraging technology to deliver a consumer-centric healthcare experience. HIMS operates primarily through its e-commerce-oriented telemedicine platform, facilitating consultations, prescriptions, and the delivery of branded and generic medications to patients’ doors. The business operates a vertically integrated model, owning critical aspects of the patient journey: marketing, patient intake, provider networks, prescription fulfillment, and ongoing customer engagement. HIMS’s digital infrastructure enables patient onboarding, medical assessment, provider matching, prescription approvals, and refills, all handled remotely through web and mobile interfaces. This streamlined approach reduces friction, enhances privacy, and increases convenience, thereby widening access to care and nurturing strong patient loyalty.

💰 Revenue Streams & Monetisation Model

HIMS generates revenue primarily through the sale of prescription and over-the-counter products on a direct-to-consumer (DTC) basis. Its two main consumer-facing brands—’Hims’ for men and ‘Hers’ for women—each offer tailored product portfolios across categories like hair loss, sexual health, dermatology, mental health, and wellness. Key revenue streams include: - **Subscription-Based Product Sales:** Recurring revenue from monthly and quarterly subscriptions, with patients purchasing medications or products on an auto-renewing basis. - **Telehealth Consultation Fees:** Fees charged for digital provider consultations, both for initial intake and follow-ups, including asynchronous and synchronous telemedicine encounters. - **A La Carte Product Sales:** One-time purchases of health and wellness products, such as skin care, supplements, and personal care treatments. - **Partnerships and B2B Initiatives:** Emerging revenue from employer-health or payer partnerships expanding HIMS’s reach across different customer segments. The subscription model is core to monetization, driving predictable revenue, enhanced customer lifetime value, and high retention rates due to the ongoing nature of many treated conditions.

🧠 Competitive Advantages & Market Positioning

HIMS is positioned as a technology-first, consumer-friendly healthcare brand with several structural advantages: - **Brand Trust and Consumer Appeal:** Distinct branding and destigmatization of previously sensitive health topics foster strong consumer engagement and brand advocacy, especially among Millennials and Gen Z. - **Integrated Telehealth Platform:** The proprietary digital care platform offers seamless access, personalized treatment protocols, and a streamlined user experience, enhancing both customer satisfaction and operational scalability. - **Agile Product Launch Cycle:** HIMS’s DTC model enables rapid iteration and expansion into new therapeutic categories based on market signals and consumer demand, compared to traditional healthcare providers. - **Data-Driven Operations:** Direct patient relationships and digital touchpoints afford HIMS a wealth of data to optimize patient retention, cohort performance, marketing ROI, and cross-sell opportunities. - **Low-Cost Structure:** By eschewing physical clinics and leveraging telemedicine, HIMS maintains a leaner cost base relative to brick-and-mortar competitors, which can be translated into competitive pricing or higher operating margins. While the market for telehealth competitors continues to expand, HIMS’s focus on brand intimacy, digital engagement, and recurring revenue distinguishes it from pure-play software platforms and traditional retail pharmacy chains.

🚀 Multi-Year Growth Drivers

Several secular trends and company-specific strategies underpin HIMS’s long-term growth trajectory: - **Expansion of Addressable Market:** Consumerization of healthcare and growing comfort with telemedicine continue to increase adoption rates. Digital natives, who constitute a growing portion of healthcare spenders, are more likely to adopt DTC health and wellness models. - **Product Portfolio Diversification:** Expansion into new medical verticals—ranging from mental health services to primary care offerings—increases the company’s share-of-wallet and supports upselling/cross-selling. - **Geographic Expansion Opportunities:** While HIMS’s core business has focused on the U.S. market, regulatory clarity and local partnerships may unlock international markets with similar unmet needs. - **Improved Telehealth Infrastructure & Regulation:** Favorable regulatory advancements around telemedicine care provision, remote prescribing, and pharmacy fulfillment help broaden HIMS’s accessibility and scalability. - **Partnerships and Channel Expansion:** Strategic collaborations with employers, insurers, or health systems can drive B2B growth alongside core DTC channels, increasing the company’s market penetration.

⚠ Risk Factors to Monitor

Investors should remain aware of several potential risks inherent in HIMS’s operating environment and business model: - **Regulatory and Compliance Uncertainty:** Telemedicine remains subject to evolving state and federal regulations regarding remote prescribing and practice of medicine, which can impact service cadence and addressable market. - **Competitive Dynamics:** Low barriers to entry in DTC healthcare (especially for categories like dermatology and wellness) invite new entrants and large healthcare incumbents, driving competition on pricing, marketing, and differentiation. - **Customer Retention and Churn:** Subscription-based revenue relies on long-term customer engagement; lackluster adherence or condition improvement could increase churn, pressuring growth and margins. - **Data Security and Privacy:** As a custodian of sensitive health data, HIMS faces heightened cybersecurity risks and reputational damage potential from any breaches or lapses in data privacy. - **Supply Chain Reliability:** Fulfillment of medications hinges on reliable third-party pharmacy and logistics partners. Disruptions may damage brand trust or increase costs.

📊 Valuation & Market View

HIMS is typically valued using a blend of revenue-based multiples and forward growth estimates that reflect both its technology profile and healthcare sector exposure. As a high-growth, high-potential telehealth business, HIMS often trades at a premium to traditional healthcare providers and pharmacies, justified by its scalable model, recurring revenue, and significant optionality from product and market expansion. Asset-light operations and improving margins are positive, but profitability may remain variable due to sales and marketing investment to acquire and retain customers. The long-term value proposition hinges on continued market share growth, expansion into new verticals, and the company’s ability to cement consumer loyalty. Strategic partnerships, expanded service lines, and proven ability to unlock cross-sell/upsell potential with the expanding user base could meaningfully alter valuation trajectories. Analysts and investors will closely monitor subscriber growth, average revenue per user (ARPU), contribution margins, and LTV:CAC ratios to gauge scalability and value-creation potential. Comparisons to other digital health and DTC peers can provide relative context but must be adjusted for growth rates and margin structures.

🔍 Investment Takeaway

Hims & Hers Health Inc (HIMS) offers a compelling opportunity within the digital health and direct-to-consumer healthcare sectors, leveraging strong brand equity, an integrated technology platform, and a scalable business model. The company’s focus on stigmatized or neglected conditions, subscription-driven recurring revenue, and rapid product innovation places it at the intersection of key secular trends reshaping healthcare consumption. Prospective investors must weigh the platform’s broad optionality and long-term upside potential against regulatory, executional, and competitive risks inherent to telehealth. HIMS’s long-term value will be determined by its ability to maintain high retention, expand its addressable market, and navigate the evolving competitive and regulatory landscape. For investors with a tolerance for volatility and an appetite for disruption within healthcare, HIMS warrants consideration as a growth-oriented component within a diversified portfolio.

⚠ AI-generated — informational only. Validate using filings before investing.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"HIMS reported a revenue of $617.8M for the fiscal year ended December 31, 2025, with a net income of $20.6M and EPS of $0.09. Despite generating significant top-line growth, the company faced challenges, demonstrating a decline in market performance with a 1-year change of -42.96% and YTD change of -36.13%. Operating cash flow was $61.3M; however, capital expenditures and negative free cash flow of -$9.7M highlight investments exceeding cash generation. The company shows debt worth $1.04B against assets of $2.15B, leading to leverage concerns. Investors should note that the absence of dividends and the notable price drop could affect shareholder sentiment. Analysts have a price target consensus of $29.92, indicating potential upside from the current price of $21.34."

Revenue Growth

Neutral

Strong revenue of $617.8M indicates growth, but further analysis needed on sustainability.

Profitability

Fair

Positive net income but overall profitability metrics are modest.

Cash Flow Quality

Neutral

Negative free cash flow and capital expenditures exceeding operational cash flow are concerning.

Leverage & Balance Sheet

Caution

High levels of net debt relative to equity raises leverage concerns.

Shareholder Returns

Neutral

Negative share price performance and no dividends impact overall shareholder returns.

Analyst Sentiment & Valuation

Neutral

Analyst price targets suggest some upside, but market performance is a concern.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Hims & Hers delivered strong Q4 and FY25 growth with accelerating subscriber engagement, expanding personalized treatments, and robust contributions from Hers and weight loss. Management highlighted rapid innovation (Labs and hormone therapies), meaningful international expansion via M&A, and heavy investment in diagnostics, AI, and fulfillment infrastructure. The tone was confident, underscored by improving unit economics, profitability, and positive free cash flow, with a multiyear runway and ambitious 2030 targets, while noting transition-related headwinds and execution needs as the model scales globally.

Growth

  • Subscribers surpassed 2.5 million at year-end 2025; nearly 1 million net adds since end of 2023
  • Q4 revenue $618M, up 28% YoY; FY25 revenue $2.35B, up 59% YoY
  • Monthly revenue per average subscriber rose 11% YoY to $83 in Q4
  • Hims brand delivered >30% YoY revenue growth in 2025 despite pivot-related headwinds; ~0.5M subscribers on daily sexual health solutions grew >30% YoY
  • Hers posted triple-digit revenue growth in 2025 and comprised nearly 40% of U.S. revenue
  • Weight loss offering reached a $100M revenue run-rate in <7 months post-launch (excluding compounded GLP-1s)

Business Development

  • Launched three new entry points in 2025: Labs, low testosterone support, and menopause/perimenopause therapies (within 90 days)
  • Early adoption accelerated post–Super Bowl campaign; management expects each of testosterone, menopause, and Labs to surpass $100M annual revenue in the near term
  • Over 70% of Labs customers may be eligible for treatment plans; AI-supported lab readouts cover 130+ biomarkers
  • Proactive messaging in weight loss increased weight-logging frequency by >50%
  • M&A: acquired ZAVA (U.K./EU), Livewell (Canada), YourBio (at-home blood collection); signed agreement to acquire Eucalyptus (expands to Australia and Japan)

Financials

  • Q4 revenue $618M (+28% YoY); FY25 revenue $2.35B (+59% YoY)
  • Approx. 65% of subscribers (1.6M) use personalized treatments
  • Hers accounted for nearly 40% of U.S. revenue in 2025
  • Company achieved adjusted EBITDA and net income profitability and generated positive free cash flow
  • GLP-1s provided meaningful acceleration, while only a small minority of subscribers use compounded GLP-1 treatments

Capital & Funding

  • Invested >$300M over the last 3 years in facilities; footprint now >1M sq. ft. across pharmacy operations, lab testing, and R&D (including peptide therapies)
  • Ongoing M&A to expand internationally (ZAVA, Livewell, YourBio; signed to acquire Eucalyptus)
  • Positive free cash flow supports continued investment in new offerings and infrastructure

Operations & Strategy

  • Consumer-centric platform expanding across sexual health, dermatology, weight loss, hormones, and diagnostics; moving toward proactive and preventative care
  • Personalized solutions include tailored dosing, combination therapies, alternative form factors, and data-driven tools; ~65% of subscribers on personalized treatments
  • AI layer to define/refine precision treatments, enable proactive conversational support, and automate admin workflows
  • Diagnostics roadmap includes at-home testing (via YourBio), integration of wearables/CGMs/fitness trackers, and future polygenic risk scores
  • Infrastructure enables personalized treatments and custom formulations that combine pharmaceuticals and supplements, independent of insurance or local pharmacy stock

Market & Outlook

  • U.S. injectable GLP-1 prices have fallen >80% over the past 18 months, reflecting a shift toward consumer-centric distribution
  • Hims brand to continue transitioning in 2026 away from generic on-demand sexual solutions; retention expected to benefit from daily sexual health and testosterone support
  • Hers U.S. to deepen across weight loss, dermatology, menopause, and diagnostics
  • International business targeted to exceed $1B annual revenue within 3 years (post Eucalyptus close), expanding across the U.K./EU, Canada, Australia, and Japan
  • Long-term 2030 targets: $6.5B revenue and $1.3B adjusted EBITDA

Risks Or Headwinds

  • Near-term headwinds from pivoting away from generic on-demand sexual solutions
  • Management acknowledges expected challenges as the industry transitions to consumer-centric models
  • GLP-1 market disruption and U.S. price declines
  • Execution and integration required to close and scale recent acquisitions (e.g., Eucalyptus) and achieve international targets

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the HIMS Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
📁

SEC Filings (HIMS)

© 2026 Stock Market Info — Hims & Hers Health, Inc. (HIMS) Financial Profile